Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Primary Care
Antifibrotic
Questions discussed in this category
Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?
1 Answer available
18565
Papers discussed in this category
American journal of respiratory and critical care medicine, 2019 Jul 15
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
PloS one, 2022 Feb 03
Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study.
Respiration; international review of thoracic diseases, 2022 Nov 10
Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years.
Related Topics in Primary Care
Lung Cancer
Workload
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Oncology
Palliation
Neuro-Oncology
Gastrointestinal Cancers